Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H31N6O5P.C4H4O4 |
| Molecular Weight | 606.5647 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C\C(O)=O.CC(C)OC(=O)C(C)(C)N[P@@](=O)(CO[C@H](C)CN1C=NC2=C(N)N=CN=C12)OC3=CC=CC=C3
InChI
InChIKey=FTBUYHOGDVLBTE-AEMBBCOKSA-N
InChI=1S/C22H31N6O5P.C4H4O4/c1-15(2)32-21(29)22(4,5)27-34(30,33-17-9-7-6-8-10-17)14-31-16(3)11-28-13-26-18-19(23)24-12-25-20(18)28;5-3(6)1-2-4(7)8/h6-10,12-13,15-16H,11,14H2,1-5H3,(H,27,30)(H2,23,24,25);1-2H,(H,5,6)(H,7,8)/b;2-1+/t16-,34-;/m1./s1
| Molecular Formula | C22H31N6O5P |
| Molecular Weight | 490.4925 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | C4H4O4 |
| Molecular Weight | 116.0722 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/20439609 and http://ir.chimerix.com/releasedetail.cfm?releaseid=752310
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/20439609 and http://ir.chimerix.com/releasedetail.cfm?releaseid=752310
CMX157 is a lipid (1-0-hexadecyloxypropyl) conjugate of the acyclic nucleotide analog tenofovir (TFV) with activity against both wild-type and antiretroviral drug-resistant HIV strains, including multidrug nucleoside/nucleotide analog-resistant viruses. CMX157 was designed to mimic lysophosphatidylcholine to take advantage of natural lipid uptake pathways and to achieve high intracellular concentrations of the active antiviral, with the aim of increasing the effectiveness of TFV against wild-type and mutant HIV. CMX157 demonstrated potential to effectively suppress replication of multiNRTI-resistant (MNR) HIV that cannot be treated with any currently available NRTIs, including TDF. It is in phase II clinical trial for HIV infections in USA and phase Ib portion of the phase I/II trial for Hepatitis B in Thailand (PO).
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: HIV-1, subtype A 92RW009 |
3.3 nM [EC50] | ||
Target ID: HIV-2 |
3.5 nM [EC50] | ||
Target ID: HBV replication |
0.49 µM [EC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Sample Use Guides
| Substance Class |
Chemical
Created
by
admin
on
Edited
Thu Jul 06 20:40:07 UTC 2023
by
admin
on
Thu Jul 06 20:40:07 UTC 2023
|
| Record UNII |
497RW32J2X
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
154572825
Created by
admin on Thu Jul 06 20:40:07 UTC 2023 , Edited by admin on Thu Jul 06 20:40:07 UTC 2023
|
PRIMARY | |||
|
1571076-41-9
Created by
admin on Thu Jul 06 20:40:07 UTC 2023 , Edited by admin on Thu Jul 06 20:40:07 UTC 2023
|
PRIMARY | |||
|
497RW32J2X
Created by
admin on Thu Jul 06 20:40:07 UTC 2023 , Edited by admin on Thu Jul 06 20:40:07 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
